NASDAQ:OMER - Nasdaq - US6821431029 - Common Stock
OMEROS CORP
NASDAQ:OMER (1/21/2025, 8:18:34 PM)
After market: 9.15 0 (0%)9.15
-0.18 (-1.93%)
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -42.93% | ||
ROE | N/A | ||
Debt/Equity | N/A |
Omeros Corp. operates as a biopharmaceutical company. The company is headquartered in Seattle, Washington and currently employs 198 full-time employees. The company went IPO on 2009-10-08. The firm is focused on discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders, including complement-mediated diseases, cancers, and addictive and compulsive disorders. Its lead MASP-2 inhibitor, narsoplimab, targets the lectin pathway of complement and is the subject of a biologics license application pending before FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Its long-acting MASP-2 inhibitor, OMS1029, is in a phase I multi-ascending-dose clinical trial. OMS906, its inhibitor of MASP-3, the key activator of the alternative pathway of complement, is advancing in clinical programs for paroxysmal nocturnal hemoglobinuria and complement 3 glomerulopathy. The Company’s lead phosphodiesterase 7 inhibitor OMS527 is in clinical development for the treatment of cocaine use disorders.
OMEROS CORP
201 Elliott Avenue West
Seattle WASHINGTON 98119 US
CEO: Gregory A. Demopulos
Employees: 198
Company Website: https://www.omeros.com/
Investor Relations: https://investor.omeros.com/
Phone: 12066765000
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
LLY | ELI LILLY & CO | 72.99 | 704.73B | ||
NVO | NOVO-NORDISK A/S-SPONS ADR | 27.38 | 359.88B | ||
JNJ | JOHNSON & JOHNSON | 14.47 | 356.69B | ||
MRK | MERCK & CO. INC. | 16.17 | 243.45B | ||
AZN | ASTRAZENECA PLC-SPONS ADR | 17.84 | 210.75B | ||
NVS | NOVARTIS AG-SPONSORED ADR | 13.37 | 199.39B | ||
PFE | PFIZER INC | 10.33 | 150.97B | ||
SNY | SANOFI-ADR | 12.43 | 129.60B | ||
BMY | BRISTOL-MYERS SQUIBB CO | 48.75 | 115.69B | ||
ZTS | ZOETIS INC | 29.09 | 75.58B | ||
GSK | GSK PLC-SPON ADR | 8.26 | 68.92B | ||
TAK | TAKEDA PHARMACEUTIC-SP ADR | 21.83 | 41.53B |